CompletedNot Applicable

Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma

Germany38 participantsStarted 2021-02-01

Plain-language summary

The aim of the prospective, unicenter proof-of-principle study is to investigate the anti-neoplastic effectiveness of NIPP against CIN III lesions. * The aim of this project is to evaluate the potential of a previous NIPP treatment to significantly reduce the invasiveness of the LEEP excision. * Another aim of this study is to investigate cellular / molecular effects of NIPP following the in-vivo treatment of the cervix using molecular biological methods. For this purpose, tissue treated with plasma is taken after defined periods of time by mini biopsy and examined using molecular biological, histological and microscopic methods.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed CIN III * Clearly visible transformation zone of the portio and margins of the lesions according to T1 / T2 * signed written consent Exclusion Criteria: * Not fully visible transformation zone * Indication of an invasive disease * Serious cardiovascular diseases * Patients who only want to undergo a LEEP excision

What they're measuring

Rate of histological complete remission

Timeframe: 8 Weeks

Trial details

NCT IDNCT04753073

SponsorUniversity Hospital Tuebingen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-30

View on ClinicalTrials.gov More Cervical Intraepithelial Neoplasia III trials